Bilaal.Raja
Company record

COO  COOPER COMPANIES, INC.

Trailing twelve months to 2026-07-31, as filed 2026-09-09 and not restated since.
Healthcare

Scale

Market cap
$11.1bn
Revenue TTM
$4.2bn
Net income TTM
$570m
Free cash flow
$678m
Composite score
51.6
Sector rank
#639

Valuation

P / E
19.5
EV / EBITDA
14.5
EV / sales
3.2
FCF yield
6.11%
Yield vs 10-yr
-0.14pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
13.5%
EBITDA margin
21.9%
ROE
6.8%
ROIC
5.1%
Revenue growth
4.7%

Insider activity, last 90 days

Net open-market
$1.88m
Buyers
3
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In the nine months ended July 31, 2026 and July 31, 2025, the growth experienced across all categories was positively impacted by favorable foreign exchange rate fluctuations of approximately $53.7 million and $4.4 million, respectively. • Toric and multifocal grew primarily through the success of Biofinity and MyDay. • Sphere, other grew primarily through MiSight and MyDay. • "Other" products represented less than 1% of net sales in the nine months ended July 31, 2026 and 2025. Management’s Discussion and Analysis of Financial Condition and Results of Operations In the three months ended July 31, 2026, CooperVision's net sales in the Americas declined due to reductions in U.S. …COOPER COMPANIES, INC., 10-Q, period ended 2026-07-31, filed 2026-09-09

Read the full passage →